News ReleasesPROTOX THERAPEUTICS TO PRESENT AT BIOSQUARE 2007 Vancouver, British Columbia, March 8, 2007 –Protox TM Therapeutics Inc. (TSX-V:PRX) announced today that President and Chief Executive Officer Dr. Fahar Merchant will be presenting at the BioSquare 2007 conference to be held at the Lyon Convention Centre in Lyon, France, March 12 to 14. Dr. Merchant’s presentation will provide an overview and update on recent developments at the company and will take place on Tuesday, March 13 at 5:15PM in the Rhône 1 room. BioSquare has become one of the premier international partnering events in Europe bringing together biotech executive, industry leaders and investors representing more than 800 life sciences companies from over 30 countries About Protox Protox Therapeutics is a leader in advancing novel, targeted protein toxin therapeutics for treatment of cancer and other proliferative diseases. The company is actively developing two distinct but complementary platforms, INxinTM and PORxin, and currently has three clinical programs in development. A Phase IIa clinical trial into the use of PRX321 (INxin) for the treatment of primary brain cancer has been completed and the drug has received Fast Track Designation and Orphan Drug Status from the US FDA. In addition, a Phase I trial has been completed for PRX321 to treat patients with renal cell carcinoma and non-small cell lung cancer. Patient enrolment is underway for a Phase I clinical study into the use of PRX302 (PORxin) to treat localized prostate cancer. PRX302 has also been approved by Health Canada to commence a Phase I clinical study for the treatment of benign prostatic hyperplasia. NO REGULATORY AUTHORITY HAS APPROVED OR DISAPPROVED THE CONTENT OF THIS RELEASE. THE TSX VENTURE EXCHANGE DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. Certain statements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on Protox’ current beliefs as well as assumptions made by and information currently available to Protox and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by Protox in its public securities filings; actual events may differ materially from current expectations. Protox disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. For further information visit our website at www.protoxtherapeutics.com, or contact: James Beesley
Michael Moore |
2006 Protox Therapeutics Inc. All Rights Reserved. Legal Disclaimer. |